The evolving landscape of value-based care (VBC) in 2024 is witnessing a dynamic shift, driven by nuanced changes that hold the promise of transforming healthcare delivery, quality assessment, and reimbursement methodologies. Here are the key trends that will need to be top of mind for provider organizations that are transitioning to VBC, or looking to improve their performance under value-based contracts.
As we look into the future, 2024 promises a profound transformation. Here are five areas of focus for the upcoming year.
Quantum Health's Chief Product Officer, Dan Shur talks about the company’s recent Index Report on the changing landscape of healthcare consultants.
Goldman Sachs’s new fund—its first dedicated to life sciences—will focus on early- to mid-stage therapeutics companies with multiple assets. Genetic medicine, cell therapy, immunotherapy, and artificial intelligence are among the areas of investment interest for the firm.
At RSNA, three major trends stood out: the integration of artificial intelligence (AI), a renewed focus on health equity, and a dedicated effort to enhance the patient experience.
Last week, HHS finalized a new rule that requires healthcare AI developers to provide more data about their products to customers, which could aid providers in determining AI tools’ risks and effectiveness. Some AI leaders believe the new guardrails are a step in the right direction, and others are skeptical about whether the new rules are necessary or will be effective.
Despite artificial intelligence’s growing role in drug research, a fully AI-generated molecule has yet to advance from discovery all the way through clinical development. A novel molecule may eventually meet that goal, but some industry observers say it’s too early to focus on winning a race that has many twists and turns yet to come.
Life science startups account for just 8% of global startups but are the second largest driver of investment capital, according to a 2022 report. Cell and gene therapies, machine learning technologies and other innovations have spurred the growth of life science companies. But the life science sector gained attention during the Covid-19 pandemic in a way […]
The integration of AI into cardiology workflows can help triage care automatically, ensuring the right physicians weigh in on patient data at the right time which may potentially improve clinical outcomes for all patients in need.
Through rigorous validation processes, unwavering transparency, gradual implementation, and a steadfast commitment to preserving the human touch, healthcare IT providers can unequivocally demonstrate that AI is a reliable and trustworthy ally in the intricate and evolving landscape of healthcare.
I work as a cardiologist for a multi-specialty group that sees patients both in capitated payer and fee-for-service environments. This diverse practice gives me the experience to know where insurance providers will find value or what they will likely pay for. As these protocols become more scientifically validated, AI is going to help the entire healthcare system to identify at-risk patients quickly and accurately.
To digitize healthcare and lean on the emerging technologies is to find the opportunity within the relationship between machine and human to augment humans’ ability to be human – to empathize and provide the compassionate touch to care.
Chief Medical Officer, Dr. Mark Pratt of Altera Digital Health addresses the way technology can be leveraged to improve healthcare in rural communities.
Putting all the AI pieces into place effectively requires clarity of what organizations want to accomplish - and for much of healthcare, the Quadruple Aim remains at the very top. Although how to get there will look different, clarity on principles and values that will guide the development of what comes next is paramount to setting us up for years to come.
AI technologies have a role in the life sciences that goes beyond drug discovery. A panel at the MedCity News INVEST conference in Dallas discussed how new tech platforms help speed up the process of recruiting patients and running clinical trials.
At HLTH, Shaun Miller — Cedars-Sinai's chief medical information officer — pointed out one thing he thinks healthcare AI companies haven’t quite gotten right yet. He said he would “really like there to be a lot more recognition around the personalization of AI and the ability for technology to understand that not every clinician is the same.”
In a preview before the official announcement at HLTH last week, Microsoft executives and its hospital customers shared use cases of how its suite of AI tools can be used by health systems to improve healthcare delivery and alleviate provider burnout.
The FDA's digital health advisory committee will discuss technologies such as artificial intelligence and machine learning, virtual reality, and digital therapeutics as well as topics like decentralized clinical trials and patient-generated health data. Committee member nominations are due in December.